The Food and Drug Administration announced approval of a new gene therapy for Sanfilippo syndrome type A, an ultra‑rare neurodegenerative disorder sometimes referred to in media as childhood Alzheimer’s. The therapy, named Fayuvi, was developed by Ultragenyx. STAT reporter Jason Mast published the approval notice on Sept. 17, 2026.
The STAT article excerpt states that this is the first drug specifically approved to treat Sanfilippo syndrome. Ultragenyx had not immediately disclosed pricing in the portion of the story that is publicly available.
According to the report, Fayuvi is the product developed by Ultragenyx that received FDA approval for Sanfilippo syndrome type A. No additional technical or clinical details about the therapy — including mechanism of action, vector platform, route of administration, dosing, manufacturing, or regulatory pathway — were reported in the available excerpt.
The company’s pricing, commercial launch plans, and any patient access programs were not released in the portion of the article provided.
The article includes a quoted reaction from Cara O’Neill, chief science officer of the Cure Sanfilippo Foundation. O’Neill said the approval would be profoundly meaningful for families affected by the disease and that it could change the message clinicians and genetic counselors deliver at diagnosis. She described the disease as "really horrific" and emphasized that an approved therapy would provide hope and an actionable treatment plan rather than only supportive care recommendations.
A photograph included with the article shows a patient with Sanfilippo syndrome type A following gene therapy in an earlier context; the caption credits the Cure Sanfilippo Foundation. Beyond this advocacy perspective, the excerpt did not report other stakeholder reactions such as those from clinicians, regulatory experts, or payers.
The publicly available excerpt of the STAT report omits multiple items clinicians and other stakeholders typically seek after an approval announcement. The following key details were not reported in the source excerpt:
Because these items are central to clinical decision‑making, their absence in the excerpt means clinicians should not rely solely on the news summary for implementation or counseling.
The approval of the first therapy specifically for Sanfilippo syndrome type A is potentially practice‑changing for a disease historically managed with supportive care only. However, the excerpted article does not provide the evidence base required to assess benefit‑risk balance, identify appropriate candidates, or implement therapy safely.
Clinicians, genetic counselors, and specialists should seek the following primary sources for authoritative information before making treatment decisions:
Until those documents are reviewed, clinicians should treat this news as a high‑level regulatory update rather than a basis for immediate clinical implementation.
This report was authored by Jason Mast and dated Sept. 17, 2026. The full STAT article was published as a STAT+ exclusive and is behind STAT’s subscription paywall; the excerpt available publicly conveyed the core approval announcement, the developer name, an advocacy quote, and that pricing had not been released. The STAT excerpt did not include detailed clinical, regulatory, or commercial information. For comprehensive and actionable details, consult FDA documents, Ultragenyx communications, and primary clinical sources.
Note: This rewritten summary is strictly limited to facts and quotations presented in the available STAT excerpt. Where the STAT excerpt did not report specific data or details, that absence is noted rather than being supplemented with external information.